InspireMD Ltd.

168 articles with InspireMD Ltd.

• InspireMD Reports First Quarter 2022 Financial Results and Business Update

  5/10/2022

  InspireMD, Inc. announced financial and operating results for the first quarter ended March 31, 2022.

• InspireMD to Report First Quarter 2022 Financial Results on May 10, 2022 and Provide Corporate Business Update

  4/28/2022

  InspireMD, Inc. announced it will report first quarter 2022 financial results on Tuesday, May 10, 2022, before the market opens.

• InspireMD to Host Key Opinion Leader Event on Carotid Artery Disease Management and Stroke Prevention in combination with the CGuard™ Stent Platform & MicroNet™ PortfolioTuesday, March 22nd @ 2 p.m. ET

  3/16/2022

  InspireMD, Inc., a global developer of the CGuard™ Embolic Prevention Stent System device for the treatment of Carotid Artery Disease and stroke prevention, announced that it will host a Key Opinion Leader webinar on its CGuard Stent Platform and it’s MicroNet™ portfolio on Tuesday, March 22, 2022 at 2 p.m. Eastern Time.

• InspireMD Reports Fourth Quarter and Year-End 2021 Financial Results

  3/8/2022

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced financial and operating results for the fourth quarter and year ended December 31, 2021.

• InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application

  2/28/2022

  InspireMD, Inc. today announced its CGuard Carotid Stent, utilizing its proprietary MicroNet mesh, will be included as a device option for stenting in the CREST-2 Trial.

• InspireMD to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022 and Provide Corporate Business Update

  2/22/2022

  InspireMD, Inc. announces it will report fourth quarter and full year 2021 financial results on Tuesday, March 8, 2022, before the market opens.

• InspireMD Announces Adnan Siddiqui, MD, PhD as a Member of its Scientific Advisory Board and Strategic Advisor

  2/15/2022

  InspireMD, Inc. today announced the appointment of Adnan Siddiqui, MD, PhD, FAANS, FACS, FAHA to the Company’s Scientific Advisory Board.

• InspireMD Announces Live Case Broadcast at ISET 2022 Conference Following the Supplement Approval by the FDA Regarding its Pivotal C-Guardians TrialLive Case will be Broadcasted Today at 11:00am ET

  1/18/2022

  InspireMD, Inc. announced that a live case demonstration featuring CGuard™ EPS will be broadcasted at the International Symposium on Endovascular Therapy 2022 Conference by Dr. Chris Metzger, Chair of Clinical Research at Ballad Health on Tuesday, January 18, 2022.

• InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update

  11/9/2021

  InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update

• InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions

  11/3/2021

  InspireMD, Inc. announced that results from the investigator-initiated SIBERIA randomized clinical trial of CGuard EPS, that evaluated the peri-procedural and 30-day silent brain infarcts associated with the use of its MicroNet™ covered stent versus a conventional “workhorse” open-cell Acculink™ nitinol stent were published this week.

• InspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business UpdateEarnings Conference Call to be held Tuesday, November 9, 2021, at 8:30 a.m. ET

  10/26/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention Stent System device for the treatment of Carotid Artery Disease and stroke prevention, announces it will report third quarter 2021 financial results on Tuesday, November 9, 2021, before the market opens.

• InspireMD Announces Strong Second Quarter 2021 Financial Results

  8/10/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced financial and operating results as of and for the second quarter ended June 30, 2021.

• InspireMD to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021, and Provide Corporate UpdateEarnings conference call to be held Tuesday, August 10, 2021, at 8:30 a.m. ET

  8/4/2021

  InspireMD, Inc. today announces it will report fiscal first quarter 2021 financial results on Tuesday, August 10, 2021, before the market opens. Management will host a conference call on Tuesday, August 10, at 8:30 a.m. ET to review financial results

• InspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021

  6/2/2021

  InspireMD, Inc. developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by Carotid Artery Disease, announced that Chief Executive Officer Marvin Slosman will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10, 2021.

• InspireMD Announces Warrants Exchange Listing Transfer to NasdaqTickers to be NSPRW and NSPRZ

  5/27/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced the Company’s warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market.

• InspireMD Commences Trading on Nasdaq-CMTicker to remain NSPR

  5/21/2021

  TEL AVIV, Israel, May 21, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), today announced that the Company’s shares will commence trading on The Nasdaq Capital Market (“Nasdaq-CM”), today, May 21, 2021, under the symbol NSPR. InspireMD CEO Marvin Slosman said, “The trading of our shares on the Nasdaq Capital Market is a yet another very important step in t

• InspireMD to Participate at the Investor Summit Conference and Present to Investors on May 17, 2021

  5/14/2021

  InspireMD, Inc. developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced that management will participate at the Investor Summit Conference on May 17, 2021.

• InspireMD Announces Appointment of Katie Arnold to Board of Directors

  5/12/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced it has appointed seasoned marketing executive Kathryn Arnold to its Board of Directors.

• InspireMD Announces First Quarter 2021 Financial Results

  5/11/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced financial and operating results for the first quarter ended March 31, 2021.

• InspireMD Announces Stock Exchange Listing Transfer to NasdaqTicker to remain NSPR

  5/10/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced the Company’s shares have been approved for listing on The Nasdaq Capital Market.